Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $63.00 price target on the stock.
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers [Yahoo! Finance]
Arcturus Therapeutics to Attend Upcoming Investor Conferences